Solid post, Closet.
It's easy to believe when something agrees with your preconceived notion.
The upshot of much of our discussion is that NP doesn't tell the whole truth and is often materially misleading.
Don't you think saying that the protocol that was accepted was the one we chose is misleading when previously submitted protocols were not accepted by the FDA? The first one was rejected and the second submittal was changed. The FDA made them change to 28 days with no adjustment of the dosing regimen. When Cytodyn asked to change the dosing regimen the FDA would not allow it.
by citing a press release with historical information....see the theme
April 3rd 2020 PR -
CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks
Patients enrolled in this trial are expected to be administered leronlimab for two weeks with the primary endpoint being the mortality rate at 14 days.
If you go back to the initial protocol for mild/moderate they wanted treatment over 4 weeks.
Patients enrolled in the trial are expected to have a treatment window of 4 weeks.